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ABSTRACT
Gadolinium-based contrast agents (GBCAs) are in widespread use to enhance magnetic
resonance angiography images for evaluating vascular pathology. However, there are safety
concerns and limitations regarding the use of GBCAs. It has been shown that the magnetic
resonance imaging (MRI) signal intensity (T1-weighted images) in some of the brain’s tissues
is higher for patients who had multiple exposures to GBCAs compared to patients who had
never had exposure to GBCAs. This implies that GBCAs are not sufficiently removed from
body such that GBCAs may potentially have long-term effects on the human body. These
potential safety concerns have led to an increased interest in alternative contrast agents.
Methemoglobin (metHb) and oxygen-free hemoglobin (HHb) are two forms of
hemoglobin with paramagnetic properties. It has been shown that the T1-weighted signal
intensity of blood is changed during MRI scans for metHb and HHb, leading to enhanced
contrast of MRI images. The ability of metHb and HHb to change the signal intensity has led to
the idea that they can be used as effective contrast agents. MetHb can be made by exposing
oxyhemoglobin (oxyHb) to nitric oxide (NO) and HHb can be made by removing the oxygen
from hemoglobin using nitrogen (N2).
In this study, a new gas delivery system was developed to make metHb and HHb. The
new gas delivery system was developed to have greater experimental control compared to the
PermSelect hollow-fiber module that was used in preliminary studies to make metHb. The
same system can be used to make HHb. Initial experiments showed significant amounts of
undesired nitrite (NO2-) formation during metHb formation due to the presence of contaminants
in the NO gas source. To minimize this problem, flow of NO from the gas source was bubbled
in a sodium hydroxide solution in order to reduce the NO2- concentration. Following metHb
formation, continuous delivery of NO also led to the formation of ferrous nitrosyl hemoglobin
(HbIINO). MRI studies showed that HbIINO can also increase the signal intensity of an MRI
image.
It is unknown as to whether metHb, HHb, or HbIINO would be a stronger and more
appropriate contrast agent and to what extent the T1-weighted signal is affected by the
concentration. This study evaluated T1-weighted images of blood samples over a range of
metHb and HHb concentrations, as well as HbIINO concentrations. Comparison of T1 values
showed that metHb is the strongest contrast agent and that HHb is a relatively weak contrast
agent. This study showed for the first time that HbIINO can provide a contrast effect, although
not as strong as metHb but stronger than HHb. With metHb providing a viable contrast
between 10-20%, metHb has the potential to be a safe and effective contrast agent since it can
be naturally converted back to hemoglobin.

Keywords: Roya Ayati, methemoglobin, deoxyhemoglobin, ferrous nitrosyl
hemoglobin, ferric nitrosyl hemoglobin, magnetic resonance imaging, MRI, T1 relaxation time,
T1-weighted, gadolinium-based contrast agents, nitrite, nitric oxide, hemoglobin, contrast agent
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1 Chapter 1: Introduction
Magnetic resonance imaging (MRI) is a widely utilized medical diagnosis tool for
imaging the anatomy and physiological aspects of the body. The most frequent element in the
body is the hydrogen atom, which has a single positively charged proton. Powerful magnets in
the MRI device, which produce a strong magnetic field, align a small majority of the magnetic
spin of the protons with that field (see Figure 1.1). Subsequently, a radiofrequency field at the
Larmor frequency is applied to cause this excess majority of protons to align at a 90° angle from
the magnetic field. After removing the radiofrequency field, the protons return to thermal
equilibrium by releasing energy from their excited state. The process is well modeled by
exponential decay and is characterized by a time constant that is called the T1-relaxation time.
The MRI device then receives the released energy as a signal that provides enhanced images of
the area of interest. Unlike CT scans and X-ray, MRI does not use potentially harmful ionizing
radiation.

Figure 1.1 MRI procedure. In the absence of a magnetic field, hydrogen atoms randomly move. After
applying a magnetic field, the hydrogen atoms align with the magnetic field. A radiofrequency is then
applied, changing the direction of hydrogen atoms orthogonally. After removing the radiofrequency,
hydrogen atoms realign with the magnetic field (T1-relaxation time) to release energy. Finally, the MRI
device receives the released energy as a signal to provide enhanced images.
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In specific cases of diseases (such as a cancer), a contrast agent is injected in the blood to
circulate throughout the body prior to the MRI scan. Basically, contrast agents are used to
enhance the signal of MRI images. The paramagnetic characteristics of contrast agents helps
hydrogen atoms to realign more quickly with the external magnetic field (i.e. release energy
quicker), which means a shorter T1-relaxation time and thus an enhanced signal. The
paramagnetic property is due to the presence of unpaired electrons. Paramagnetic materials are
slightly attracted to the externally magnetic field, but they do not retain magnetic properties in
the absence of a magnetic field [1].
Gadolinium-based contrast agents (GBCA) are commonly used in MRI. It has been
shown that the MRI signal intensity (T1-weighted images) in the brain is higher for patients who
had multiple exposures to GBCA compared to patients who had never had exposure to GBCA [2,
3]. For those exposed to GBCA, gadolinium has been detected in all brain areas with higher
concentrations in the globus pallidus and dentate nucleus [4]. This signifies that GBCAs are not
sufficiently removed from the body after use. Furthermore, GBCA usage is limited for people
with acute kidney injury (AKI) and chronic kidney disease (CKD) [5, 6]. Additionally, the
chance of nephrogenic systemic fibrosis (NFS) occurrence for people on dialysis is higher after
receiving GBCA [7]. Due to these GBCA limitations, there is a need to identify alternative
contrast agents that minimize accumulation in the brain and can be more broadly used. Using
naturally occurring blood species as contrast agents could be an appropriate replacement for
GBCA.
Hemoglobin is an iron-containing protein in the blood that has different forms primarily
as oxyhemoglobin (oxyHb) and deoxyhemoglobin (HHb). OxyHb is an oxygen-loaded form of
hemoglobin and HHb is an oxygen-unloaded form of hemoglobin. Methemoglobin (metHb) is a
2

paramagnetic form of hemoglobin due to the presence of 5 unpaired electrons that can also be
potentially used as an alternative contrast agent. MetHb is an oxidized form of hemoglobin in
which the iron in the heme group is in the form of 𝐹𝑒 !" (ferric) (normal hemoglobin is in the
form of 𝐹𝑒 #" (ferrous)) where it is not capable of carrying oxygen. MetHb can be produced by
either exposing oxyHb to nitric oxide (NO) gas or sodium nitrite. The reaction of sodium nitrite
with oxyHb has 13 intermediates with several unknown effects, which potentially leads to
greater side effects [8, 9]. Therefore, in this study, NO was used to produce metHb since NO has
been approved by the United States Food and Drug Administration for various human disease
treatments [10]. The total hemoglobin in human blood naturally contains 1-2% metHb due to
endogenous reactions and metHb can be tolerated at up to 20% [11]. MetHb is decreased
naturally through reductive pathways involving cytochrome b5 or flavin [12]. In addition to
metHb, HHb has paramagnetic properties which also makes it potentially useful in MRI
investigations.
The potential utilization of metHb and/or HHb as contrast agents has previously been
investigated. In assessing metHb as a contrast agent, a mixed-breed canine with hereditary
methemoglobinemia (high levels of metHb) was used to create T1-weighted images [13]. After
treating the canine with methyl blue, which decreases the amount of metHb in blood, it was
shown that the T1-weighted signal intensity of MRI decreased as the amount of metHb
decreased. In another study assessing HHb as a contrast agent [14], it was demonstrated that an
increasing amount of HHb during transient hypoxia enhanced the MRI signal. Thus, metHb and
/or HHb can potentially be used as contrast agents to replace GBCA. However, it is unknown as
to whether metHb or HHb would be a stronger and more appropriate contrast agent and to what
extent the T1-weighted signal is affected by concentration.
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As stated, NO can be used to produce metHb. NO production occurs naturally during
endogenous reactions in the body [15, 16]. NO is formed by enzymes known as NO synthases
[17]. Red blood cells act like regulators that use NO to properly deliver oxygen and remove
carbon dioxide from the tissue [18]. It is known that NO can affect many aspects of human
physiology like blood pressure, cellular apoptosis, and platelet function [19]. Therefore, small
amounts of NO in the blood can be considered safe. In order to make metHb, NO gas can be
delivered to the blood in two ways: inhaling the NO gas directly or exposing the blood to NO
gas. Inhaled NO is approved for treatment of newborns with acute respiratory failure [20].
However, a highly concentrated NO gas is required to produce the desired amount of metHb and
high concentrations can cause lung injury. The alternative is to remove blood from the body,
pass the blood through gas-permeable tubes (tubes need to be permeable to the NO), expose the
tubes to NO to make metHb, and then return the blood back to the body. Exposing blood directly
to the NO gas appears to be a potentially viable way to produce metHb from NO.
Unlike numerous reactions producing metHb via sodium nitrite, metHb can be produced
by a single reaction in which NO reacts directly with oxyHb according to:
$!.!

𝑜𝑥𝑦𝐻𝑏 + 𝑁𝑂 :⎯< 𝑚𝑒𝑡𝐻𝑏 + 𝑁𝑂!%

r1.1= k1.1(oxyHb)(NO)

(1.1)

In Equation 1.1, r1.1 is the rate of the reaction and k1.1 is the rate constant (5.4 x 106 mM-1min-1 at
pH=7, 20°C, cell-free hemoglobin) and it is associated with a near-diffusion limited reaction rate
[21]. So, using nitric NO to produce metHb seems practical, but it is necessary to see if the
reaction of NO with blood is compatible for use in the human body. Fortunately, metHb can be
reduced by NADH-cytochrome b5-metHbg reductase and other alternative pathways such as
NADPH-dependent metHb reductase, glutathione, and intracellular ascorbate [22]. MetHb
reduction has been characterized as a first-order reaction according to:
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$!.#

𝑚𝑒𝑡𝐻𝑏 :⎯< 𝐻𝐻𝑏

r1.2= k1.2(metHb)

(1.2)

The value of k1.2 is 0.004 min-1 at pH=7.2-7.6, 37°C for adult human blood [23], such that
reaction 1.2 is much slower than reaction 1.1. Basically, NO can be used to quickly create
metHb in the body, metHb can then be used for imaging, and finally, metHb can then be slowly
reduced to HHb and eventually become oxygenated to oxyHb.
By exposing blood directly to NO gas, additional reactions with hemoglobin constituents
can also occur. NO gas can react with HHb and metHb as follows:
k1.3

𝐻𝐻𝑏 + 𝑁𝑂 :< 𝐻𝑏&& 𝑁𝑂
k!.%

𝑚𝑒𝑡𝐻𝑏 + 𝑁𝑂 :< 𝐻𝑏&&& 𝑁𝑂

r1.3= k1.3(HHb)(NO)

(1.3)

r1.4= k1.4(metHb)(NO)

(1.4)

Reaction 1.3 occurs when HHb reacts with NO gas to make ferrous nitrosyl hemoglobin
(𝐻𝑏&& 𝑁𝑂) in which k1.3=1.5 x 106 mM-1min-1 for cell-free hemoglobin [24]. In reaction 1.4,
metHb reacts with NO gas to make a ferric nitrosyl hemoglobin (𝐻𝑏&&& 𝑁𝑂) in which k1.4=240
mM-1min-1 at pH=7, 20°C, cell-free hemoglobin [25]. Since reaction 1.1 is four orders of
magnitude faster than reaction 1.4 and reaction 1.2 decomposition of metHb is slow, reactions
1.2 and 1.4 are inconsequential during metHb formation with NO (reaction 1.1). Thus, metHb
can be quickly made without having it react with NO to become nitrosyl hemoglobin (until after
metHb is mostly made) or decay to HHb. Reaction 1.3 is almost as rapid as reaction 1.1 but
having mostly oxygenated blood minimizes reaction 1.3 from occurring.
According to reaction 1.4, metHb reacts with NO to produce 𝐻𝑏&&& 𝑁𝑂. This reaction
would become very significant following metHb formation as long as NO delivery continues.

5

The following reactions show that after 𝐻𝑏&&& 𝑁𝑂 is produced, it is in rapid equilibrium with
𝐻𝑏&& 𝑁𝑂" and then 𝐻𝑏&& 𝑁𝑂" rapidly reacts with water to finally make HHb.
𝐻𝑏&&& 𝑁𝑂 ↔ 𝐻𝑏&& 𝑁𝑂"

(1.5)

'()*

𝐻𝑏&& 𝑁𝑂" + 𝐻# 𝑂 :⎯< 𝐻𝐻𝑏 + 𝑁𝑂#% + 2𝐻"

(1.6)

Afterwards, according to reaction 1.3, HHb then reacts rapidly with NO to ultimately
make 𝐻𝑏&& 𝑁𝑂. Thus, at all times, the concentration of 𝐻𝑏&&& 𝑁𝑂 should be much less than the
concentration of HbIINO [26]. Since the formation of HbIINO following metHb formation will
be significant and HbIINO is paramagnetic, it will also be important to assess the impact of
HbIINO as a contrast agent in comparison to metHb and HHb.
When NO gas is delivered to oxygenated blood, dissolved oxygen can also react with NO
as follows:
$!.&

2𝑁𝑂 + 𝑂# :⎯< 2𝑁𝑂#

r1.7= k1.7(NO)2(O2)

(1.7)

𝑁𝑂# + 𝑁𝑂 ↔ 𝑁# 𝑂!

(1.8)

𝑁# 𝑂! + 𝐻# 0 → 2𝑁𝑂#% + 2𝐻"

(1.9)

In reaction 1.7, 𝑘+.- = 144 mM-2min-1 at pH=7.4, 37°C [27]. Since reaction 1.8 is a very fast
reaction, NO2 and N2O3 can be considered pseudo-steady state species. Nitrite (𝑁𝑂#% ) is the final
product of these reactions and the amount of nitrite can be determined during NO gas delivery to
the blood. The nitrite concentration can be measured by a spectrophotometer via the Griess
reaction [28].
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1.1 Scope of Project
The objective of this work is to develop a simple system to produce metHb and HbIINO
via NO gas delivery and then determine whether metHb, HbIINO, or HHb (or a combination)
would be a stronger and more appropriate contrast agent and to what extent the T1-weighted
signal is affected by concentration. The objective of this work will be achieved by the following
two Aims.
1.1.1

Aim #1. Development of NO-Delivery Device.
The delivery device will utilize blood flowing through NO-permeable tubing to control

the production of metHb, HHb, and HbIINO. Designing a new device can help control the
reactions in blood by controlling the NO delivery rate via the partial pressure of NO gas and the
tube dimensions. Having more than one reaction during metHb formation causes the presence of
byproducts like nitrate, nitrite, and 𝐻𝑏&& 𝑁𝑂 in blood. The new gas delivery system will be
developed to have greater experimental control compared to the PermSelect hollow-fiber module
(1,000 cm2 membrane model, PermSelect, Ann Arbor, MI) that was used in the preliminary
studies to make metHb. The PermSelect hollow-fiber module is a commercial device composed
of 1280 polydimethylsiloxane (PDMS) tubes to allow NO delivery to blood. The new gas
delivery system will reduce experimental costs while enabling better control of NO delivery
during metHb production. Additionally, spectrophotometric analysis will be employed to
measure the concentration of 𝐻𝑏&& 𝑁𝑂 which cannot be measured using a blood gas machine
analyzer.
1.1.2

Aim #2. MRI Analysis of Paramagnetic Hemoglobin Species.
MRI analysis is another important part of this study to help examine how metHb, HHb,

and 𝐻𝑏&& 𝑁𝑂 contribute to the MRI signal. As previously stated, it is unknown as to whether
7

metHb, HHb or HbIINO would be a stronger and more appropriate contrast agent and to what
extent the T1-weighted signal is affected by the concentration. It is important to note that no
study has ever addressed 𝐻𝑏&& 𝑁𝑂 as a potential contrast agent. Thus, T1-weighted images of
blood samples over a range of metHb, HHb, and 𝐻𝑏&& 𝑁𝑂 concentrations will be measured to
determine which hemoglobin species had the best ability to enhance MRI images.

8

2 Chapter 2: NO Delivery System and Contamination Removal
2.1 Introduction
As it was stated before, one of the aims of this study is to develop a new NO delivery
system in order to reduce experimental costs and have better control over the reactions in blood
during metHb formation. In this chapter, the NO delivery system will initially be explained, and
a model will be used to confirm the amount of NO delivery to the blood. Additionally, the
minimization of gas contamination in the NO delivery system will be explained for the purpose
of reducing the amount of NO2- in blood.

2.2 NO Delivery System
In preliminary work, a PermSelect hollow-fiber module (1,000 cm2 membrane model,
PermSelect, Ann Arbor, MI) was used to study metHb formation. NO gas was delivered to the
blood at an excessive rate due to the fixed transport area and the availability of only 100% nitric
oxide gas. Delivering an excess amount of NO gas to the blood resulted in only a fraction of the
delivered NO being converted to metHb with excess nitrite being formed. The presence of
unwanted byproducts in the blood, such as nitrite, should be potentially eliminated. Additionally,
the PermSelect hollow fiber module was relatively expensive ($500), was hard to clean, and
could only be used a few times.

9

To eliminate the above challenges, a new low-cost device was designed to control the NO
gas delivery to the blood by controlling the partial pressure of NO, as well as optimizing the
surface area of the tubes (changing the length of the tubes). Polydimethylsiloxane (PDMS)
tubing was used since it is highly permeable to NO gas. The wall thickness of the PDMS that
was used is 0.0245 cm. The diffusivity of NO in PDMS tubes is 2.34´10%. cm2/s [29].
Therefore, the characteristic transport time through the wall tubing is approximately:
tw »

(*012$34)))#
61''7)183 284''12143*

:.:#;.# 2<#

= #.!;´+:'( 2<# /) = 25 𝑆𝑒𝑐𝑜𝑛𝑑𝑠

(2.1)

For the purpose of making the NO delivery system, it was important that excess NO not
be delivered to the blood. Therefore, five PDMS tubes that were each four feet long were used
in accordance with the modeling described below to make a desirable amount of metHb. As
shown in Figure 2.1, a continuous gas flow from a 50 %NO/ 50 % N2 cylinder (Airgas, Radnor,
PA) was directed to a 1.5 Liter glass chamber. The chamber contained the five PDMS tubes
(1.47mm ID and 1.96mm OD, Scientific commodities Inc., Lake Havasu City, AZ- only one tube
shown in Figure 2.1) that were connected to the single tubes entering and exiting the chamber
using 3D printed parts. The gas flow rate was controlled by a rotameter. Using a peristaltic
pump, blood was recirculated at 20 mL/min from the blood reservoir and through the tubes
where NO was delivered from outside of the tubes to react with blood and make a desired
amount of metHb. A blood flow rate of 20 mL/min was chosen to prevent red blood cell damage
while blood was pumped through the tubes. During the formation of metHb, the hematocrit of
blood was unchanged showing that the RBCs are undamaged. The blood reservoir, which
contained 150 ml blood, was at room temperature (24 °C) and was continuously stirred at 130
rpm. The head space of the blood reservoir was exposed to room air for metHb production and to
N2 for HHb production. Detail A shows NO transport through the PDMS tubes.
10

Figure 2.1 NO delivery system. Blood was continuously pumped through 5 PDMS tubes
(only one shown) that were continuously exposed to NO/N2 gas.

MetHb formation within the PDMS tubes was modeled and compared to the experimental
results to evaluate the performance of NO delivery to the tubes. The lumen of PDMS tubes was
modeled as a steady-state plug flow reactor for species 𝑖 is as follows:
6>)
6?

= 𝑟1 + (𝑘1 )(𝑝1 𝐻1 − 𝐶1 )

(2.2)

In equation 2.2, 𝐶1 is the concentration of species 𝑖 in the lumen, 𝑟1 is the net reaction rate of
species 𝑖 based on reactions 1.1-7, 𝜏 is the residence time in the tube (lumen volume divided by
the lumen volumetric flow rate), 𝑝1 is the partial pressure of species 𝑖 in the gas side of the
chamber, and 𝐻1 is the Henry’s law coefficient for species 𝑖. Additionally, 𝑘1 is the total mass
transfer coefficient of species 𝑖, which accounts for the mass transfer coefficient of species
𝑖 through the PDMS tubes (𝑘@ABC,1 ) and the mass transfer coefficient of species 𝑖 through liquid
boundary layer located near the wall of PDMS tubes (𝑘E1F,1 ). Considering the liquid boundary
11

layer and PDMS tubes, the total mass transfer coefficient (𝑘1 ) can be determined as 1/ki=
1/𝑘@ABC,1 +1/𝑘E1F,1 . For this analysis, only NO transport was considered through the PDMS tube
walls.
For the purpose of calculating 𝑘GH , 𝑘@ABC,GH was calculated as follows:
𝑘@ABC,GH =

@4I<*+ ∙

,
-

K*+ ∙L

@

RMN./0 S

(2.3)

./0

The permeability of oxygen in PDMS tubes is 60 × 10%O

2<1 .2<
).2<# .2<KP

[30]. The NO permeability

in PDMS tubing is similar to the oxygen permeability. 𝐻GH is the Henry’s law constant of NO
QB

and it is 1930 (*< at 25 °C [31], 𝐴 is the total area of fibers, 𝑚 is the thickness of the tube wall,
and 𝑉 is the internal volume of the tubes. The standard conditions for pressure and temperature
are 1 atm and 298 K, respectively. Substituting all the parameters in equation 2.3, 𝑘@ABC,GH is
7.54 𝑚𝑖𝑛%+ . Additionally, 𝑘E1F,GH was determined by the following relation:
𝑘E1F,GH =

C0∙A1''*+ ∙R

(2.4)

A∙L
2<#

Here, 𝐷𝑖𝑓𝑓GH is the diffusivity of NO in water and it is 0.0015 <13 [32], D is the inner diameter
of tubes, and Sh is the dimensionless Sherwood number as 𝑆ℎ = 3.66 +
Additionally, 𝐺𝑧 is the Graetz number and can be calculated as 𝐺𝑧 =

:.:SST
UV×(+"

M4∙C2
X∙A

2.2%
)
342.5&

[33].

, in which 𝑅𝑒 is the

Reynolds number, 𝑆𝑐 is the Schmidt number, and L is the fiber length. 𝑅𝑒 =

Y∙Z∙A
Q

where r is the

density (1 g/cm3), v is the blood velocity in the tubes, and µ is the blood viscosity (0.513
Q

g/cm/min). This gives and Re value of 56. Additionally, 𝑆𝑐 = Y.A , in which µ is the blood
viscosity, r is the density, D is the diameter such that Sc is 342. Therefore, by substituting
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designated parameters into equation 13, 𝑘E1F,GH is 1.01 𝑚𝑖𝑛%+ . Comparing 𝑘E1F,GH and 𝑘@ABC,GH ,
it is notable that 𝑘@ABC,GH > 𝑘E1F,GH , which shows that the primary resistance to NO transport is
in the liquid boundary layer. As mentioned before, 𝑘GH can be determined using 1/ki=
1/𝑘@ABC,1 +1/𝑘E1F,1 such that 𝑘GH is 0.89 𝑚𝑖𝑛%+ .
Equation 2.2 was solved for each individual species including NO, O2, metHb, HHb,
OxyHb, HbIINO, NO2-, and NO3- from t = 0 min (inlet) to t = 0.52 min (outlet). However, the
reaction between NO and RBCs is 3000 times slower than cell-free hemoglobin [34]. Hence, the
reaction constants were considered to be 3000 less. Inlet conditions were considered to be 0.25
mM dissolved oxygen and no initial amounts of NO, NO2-, and NO3- in the inlet blood. Also, the
inlet was considered 100% oxyHb at 2.1 mM (no inlet metHb, HHb, and HbIINO). Due to the
fast reaction between NO and oxyHb, it was expected that no dissolved NO would be in the
outlet.
Figure 2.2 shows the predicted %metHb from the PDMS tube inlet (t=0) to outlet (t=
0.5), where t is the residence time, as well as saturated NO and HbIINO in the outlet. The model
predicted that after a single pass of blood through the tubes, 100% of the delivered NO should
react with oxyHb to make 19% metHb and no other hemoglobin species. Consistent with the
model, the experimental single pass conversion showed 22% conversion of oxyHb to metHb
with no other hemoglobin species detected, which shows that despite having fast reactions, gas
contamination, and frequent interactions between blood species and NO, modeling results are in
accordance with the experimental results. In previous studies using the PermSelect module,
model predictions in comparison with experimental results showed that only a fraction of
delivered NO reacted to make metHb, with the remaining NO that was delivered being
scavenged by some unknown reaction.
13

Figure 2.2 Single pass of blood through PDMS tubes.

2.3 Contamination Removal from NO/N2 Cylinder and NO Delivery System
The formation of metHb takes place as oxyHb quickly reacts with NO. However, as NO
is very reactive, it can interact with other substances (like other blood species, oxygen, etc.) to
make undesired byproducts. One of the undesired byproducts, which was detected in the blood
reservoir in noticeable amount, is NO2-. High concentration of NO2- in human blood could cause
acute toxic effects. Hence, investigating the source of NO2- formation was important. The
amount of NO2- was measured in the blood using Griess solution according to [28]. However,
there was a question as to whether NO2- measurements in whole blood or plasma were different.
Therefore, NO2- was measured in both blood and plasma and results showed the same amount of
NO2- in blood and plasma. Therefore, since there was no distinction, NO2- was only measured in
plasma.
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Figure 2.3 shows the formation of NO2- and metHb in an experiment in which NO was
delivered to oxyHb. MetHb was fully produced (1.5 mM) within 60 min and the amount of NO2increased by a constant slope. After 60 min, 16 mM of NO2- was in the blood reservoir.
According to the model, no NO2- was expected to be produced within the tubes (and thus within
the blood reservoir). High concentrations of NO2- in blood could cause acute toxic effects.
Hence, investigating the source associated with NO2- formation was important. As NO2- can be
made due to the reactions involving oxygen with NO, various reasons were considered and
examined to find the source of NO2-.
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Figure 2.3 Concentration of NO2- and metHb in blood during NO delivery.

Initially, the source of NO2- was considered to be due to oxygen in the blood reservoir
reacting with dissolved NO according to reactions 7-9. However, NO was not experimentally
detected in the blood exiting the tubes, such that NO would not be available for reaction in the
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blood reservoir. From a reaction analysis based on reactions 7-9, the overall rate of NO gas
consumption in the blood is as follows:

𝑟GH = −(𝑁𝑂)[𝑘- (𝑁𝑂)(𝑂# ) + 𝑘; (𝑚𝑒𝑡𝐻𝑏) + 𝑘! (𝐻𝐻𝑏) + 𝑘+ (𝑜𝑥𝑦𝐻𝑏)]

(2.5)

Typically, the oxyHb concentration is on the order of 2 mM [35]. Based on 21% air, the oxygen
concentration could be as high as 0.3 mM with a Henry’s law constant of 1.32 mM/atm at 23 °C.
Similarly, based on 100% NO gas exposure, the NO concentration could be as high as 2 mM
with a Henry’s law constant of 1.93 mM/atm at 23 °C [31]. Thus, during metHb formation with
𝑘! and 𝑘+ much larger than 𝑘- and 𝑘; , the NO gas consumption rate is due primarily to the
reaction with oxyHb (and HHb if present). With 𝑘. = 144 mM-2min-1, the reaction between NO
and dissolved oxygen in the blood would be slow compared to the HHb and oxyHb reaction.
Thus, 𝑁𝑂#% production during metHb formation should be negligible.
Another possible reason for NO2- formation was the potential transport of oxygen into the
NO delivery system. There was a concern that system tubing, such as the peristaltic tubing, was
permeable to oxygen. However, permeability values of the tubing are very low such that oxygen
transport should be minimal. Additionally, all fittings were inspected carefully to make sure
there was no oxygen entering the system from the chamber’s cap and other fittings.
Figure 2.4 shows the concentration of NO2- in the blood reservoir during NO delivery to
various initial concentrations of hemoglobin species. NO delivered to 100% oxyHb, 100% HHb
and 50% HHb/ 50% oxyHb essentially showed no difference in NO2- formation. Thus, the
amount of various hemoglobin species did not appear to be the reason for NO2- formation.
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Figure 2.4 Concentration of NO2- in different blood species. The amounts of NO2- in 100% oxyHb, 100% HHb,
and 50% HHb/ 50% oxyHb blood are the same.

As the amount of produced NO2- in the reservoir is linear with constant slope, it was
hypothesized that the source of NO2- is continuously supplied. According to [36], an NO cylinder
under several atm of pressure can contain impurities like N2O3, NO2, and NO2 and they can react
to make NO2- (N2O3 can react fast with water content of blood to make NO2- according to
reaction 9). Also, some impurities can be made during the production and handling of the NO
cylinder. It has been shown that NaOH solutions can be used to remove NO gas impurities [36].
Thus, NO gas prior to entering the NO delivery system was bubbled into a 200 mL glass bottle
containing 0.5 M NaOH. The NaOH solution was deoxygenated prior to use as a gas scrubber
and also the whole NO delivery system was purged of oxygen using N2. Prior to each
experiment, deoxygenated 0.1 M potassium phosphate buffer was circulated in all the NO
delivery system’s tubes to remove any remaining oxygen. The NaOH solution and potassium
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phosphate buffer were further deoxygenated by applying a vacuum to the solutions to remove
residual oxygen.
Figure 2.5 shows the amount of NO2- formed in the reservoir after passing the gas
through 0.5 M NaOH. As shown, the amount of NO2- is significantly decreased compared to
Figure 2.3. However, the amount of NO2- is still notable in the blood reservoir. For that reason, a
higher concentration of NaOH solution (1M) was used to see if it removed more impurities to
reduce NO2- but despite having a higher concentration, the NO2- content did not change.
Additionally, a 200 mL glass of deoxygenated water was used after the NaOH solution to reduce
gas contamination, but it did not reduce the NO2- amount.
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Figure 2.5 Concentration of NO2- in blood after NO was bubbled in NaOH solution. The
amount of NO2- in blood decreased as NO from NO cylinder was bubbled into NaOH solution
to remove any impurities.

18

2.4 Conclusions
In summary, following are the key points:
•

An NO delivery system was successfully designed and implemented to deliver
NO to blood to produce metHb.

•

Plug flow reactor modeling of metHb formation using the NO delivery system
was in agreement with the experimental results. The model and experimental
results agreed despite numerous potential side reactions and minor gas
contamination.

•

Although the model did not predict NO2- formation, NO2- formation was
experimentally detected. As there were likely impurities in the gas source that
caused NO2- formation in blood, the amount of NO2- formed during metHb
formation was reduced by bubbling the NO gas sources through a 0.5 M NaOH
solution.

•

The NO2- that was formed could not be completely eliminated, even when the
concentration of NaOH was increased.
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3 Chapter 3: MetHb and 𝐇𝐛𝐈𝐈 𝐍𝐎 Formation Following NO
Delivery to the Blood
3.1 Introduction
Most studies use small amount of NO gas or NO donors to make metHb in uM amounts.
However, for the purpose of using metHb as a contrast agent in MRI, metHb can be tolerated up
to 20% (approximately 0.4 mM) in human blood. Therefore, the purpose of this work is to
produce high concentrations of metHb by rapidly delivering NO to blood using the NO delivery
system described in Chapter 2. In this chapter, the following will be explained:
•

Preparing blood prior to delivering NO.

•

Producing OxyHb and HHb at desired concentrations

•

Forming metHb by exposing oxyHb to NO

•

Measuring pH dissolved NO in blood

•

Assessing Hb[[ NO and Hb[[[ NO formation

3.2 Materials and Methods
Initially, fresh bovine blood was provided from a slaughterhouse (Lehi, UT) to reduce
costs of purchasing blood. The risk of working with bovine blood was assessed by BYU risk
management to ensure all the safety aspects were considered when using the blood in the
experiments. Mammalian blood was not considered since it may have more pathogens that can
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cause infection and disease compared to bovine blood. Therefore, lab practice and personal
protective equipment were used to avoid any risk. After blood collection in a plastic bottle (1L),
the blood was quickly treated with heparin to avoid blood coagulation. Heparin solution was
made prior to blood collection by dissolving 10000 units of heparin in 20 mL deionized water to
treat 1 L of blood. Also, heparin solution was made as an isotonic solution (0.154 M NaCl) to
prevent red blood cell (RBC) damage. Blood was refrigerated at 4 °C for no more than 2 weeks.
For all studies described below, oxyHb and HHb content were measured using a blood gas
machine analyzer (BioTek Synergy Mx, Winooski, VT).
Since oxyHb is needed to make metHb, oxyHb was made by flowing blood through the
PDMS tubes while the tubes were exposed to air (the NO delivery system was used but instead
of NO exposed to the gas side of the chamber, air was exposed). Since PDMS tubes are
permeable to oxygen, 98%-100% oxyHb in 150 mL of blood was made by circulating blood
through the tubes for 30-45 min.
In some experiments, HHb was produced instead of oxyHb for investigating NO2formation. The longer blood was kept in the fridge, the blood became more deoxygenated to
amounts of HHb as high as 60%-70%. To increase the amount of HHb, HHb was made using the
system shown in Figure 3.1. Prior to the experiment, the whole system including all tubes and
the chamber were purged of air using N2 gas for 30 min. Then, blood from the reservoir was
pumped through the PDMS tubes as the headspace of blood and tubes were continuously purged
of oxygen using N2 gas. As a results, 95%-100% HHb was made in 2-3 hours.
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Figure 3.1 HHb production system. Blood from the reservoir pumped through the
tubes as the gas side of the chamber and headspace of the blood reservoir were
exposed to N2 gas.

After oxyHb was produced, metHb was made using the system shown in Figure 2.1. In
order to remove possible NOx contaminants from the NO/N2 cylinder, such as N2O3 and NO2,
gas was continuously passed through a 0.5M NaOH solution before entering the chamber
containing the PDMS tubing. The gas flow rate was 20 ml/min. The chamber contained 5 PDMS
tubes (each 4 feet long) connected at each end to a single tube that allowed blood to flow through
the PDMS tubing while the exterior of the tubing was exposed to NO gas.
The blood gas machine analyzer was used to measure the concentrations of metHb, HHb,
and oxyHb, but it was not capable of measuring Hb[[ NO and Hb[[[ NO. Hence, a
spectrophotometer (UV-1700 Shimadzu) and an excel solver were used to calculate the
percentage of all forms of hemoglobin in the blood. First, the blood was diluted in water (2 drops
of blood in 4mL of water). This was done to reduce the absorbance of the sample to a level that
the spectrophotometer could read. Next, the absorbance of the sample from 470 to 650 nm in 5
22

nm increments was measured using a cuvette with a path length of 1 cm. With this information,
an excel solver was used to calculate the concentration of each form of hemoglobin. According
to Beer’s law, A = Σ (εi L ci) where A is the absorbance, εi is the extinction coefficient of the
form of hemoglobin, L is the path length, and ci is the concentration of that form of hemoglobin.
The extinction coefficients of blood species were attained from literature such as HbIINO,
HbIIINO, metHb [37], oxyHb, and HHb [38]. Since each form of hemoglobin possesses a
different extinction coefficient spectrum, the excel solver was set up to minimize the sum
squared error between the true absorbances (measured from the spectrophotometer) and the
calculated absorbances (measured from Beer’s Law) by changing the solver’s concentrations of
each form of hemoglobin. Then, the solver would output the concentrations of each form of
hemoglobin. An agreement of the metHb concentration measured by the spectrophotometer to
the concentration measured by the blood gas machine confirmed the accuracy of the
spectrophotometric method. As a results, the concentrations of Hb[[ NO and Hb[[[ NO in blood
were able to be assessed.
3.3

Results
Figure 3.2 shows the results of 180 min blood exposure to NO. As shown, the amount of

oxyHb decreased as NO reacted with oxyHb and the amount of metHb increased until it was
fully produced at 50 min. In the presence of metHb and NO and after oxyHb depletion, Hb[[ NO
is a major hemoglobin species that is formed. HbIINO appears to reach an equilibrium with
metHb. The amount of Hb[[[ NO is negligible since considering reactions 1.3-6 once metHb is
formed, the overall reaction for metHb depletion is as follows with reaction 1.4 as the rate
controlling step:
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(3.1)
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Figure 3.2 Hemoglobin constituent concentrations in the blood reservoir following continuous exposure to NO.

To have reliable data for Figure 3.2, the experiment was repeated 5 times. The average
time in which the amount of metHb reaches maximum is 52 ± 9.4 min considering 95%
confidence interval. Also, the average amount of metHb at the maximum time is 78.6 ± 7.9% and
the amount of HbIINO at 120 min is 67.0 ± 16% considering 95% confidence interval.
During metHb formation, dissolved NO was measured in the blood reservoir using a
nitric oxide meter (Iso-No Mark Ii Nomk2 WPI World Precision instrument Sarasota, FL).
Initially, the nitric oxide meter was calibrated. The nitric oxide meter was calibrated by bubbling
various NO gas partial pressures in phosphate buffer solution. Then, the signals were read on the
nitric oxide meter after NO was saturated in the solution. The concentration of dissolved NO was
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determined from partial pressures of NO and Henry’s law and a calibration curve was provided
as a reference for future measurements.
Figure 3.3 shows the dissolved NO in the blood reservoir with time. As shown, NO was
not detected in the initial 50 min since all the delivered NO was rapidly consumed in the reaction
between NO and oxyHb to make metHb. After metHb was fully produced (at 50 min), the
amount of dissolved NO increased quickly. As a result, there is no dissolved NO in blood during
metHb formation.
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Figure 3.3 Amount of dissolved NO in blood reservoir as oxyHb is exposed to NO. The
amount of dissolved NO in blood is negligible while the reaction between oxyHb and NO is
taking place for the purpose of metHb production. After oxyHb is depleted in the blood
reservoir, the amount of dissolved NO increases.
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The blood pH was measured during metHb formation to evaluate if blood can maintain
its buffer capacity during NO delivery. As Figure 3.4 shows, the pH of blood decreased from
7.55 to 7.14 during 83 minutes of blood exposure to NO. This pH change is likely due to
hydrogen ions formed as nitrite is formed. However, the experimental results shows that blood
essentially keeps its buffer capacity during metHb formation.
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Figure 3.4 Change of blood pH during metHb production. As blood is exposed to
NO, the pH of blood did not change drastically showing that blood can keep its
buffer capacity during metHb production.
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3.4 Conclusions
In summary, the followings are the key points:
•

The reaction between metHb and NO ultimately results in Hb[[ NO formation (reaction
3.1) and the amount of Hb[[ NO can be measured using a spectrophotometric method.

•

As NO is delivered to oxyHb, the metHb amount increases until all of the oxyHb is
consumed. As metHb is fully produced, it starts to react with NO to make Hb[[ NO.

•

As the reaction between NO and oxyHb is very fast, there is no dissolved NO in blood as
long as oxyHb is present in the blood reservoir. However, as soon as oxyHb is depleted,
the amount of dissolved NO increases.

•

As the pH of blood did not change dramatically, it can be concluded that the blood is
capable of keeping its buffer capacity during metHb formation.
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4 Chapter 4: Comparison of Methemoglobin, Deoxyhemoglobin,
and Ferrous Nitrosyl Hemoglobin as Potential MRI Contrast
Agents
Chapter 4 is based on a submitted journal publication in Annals of Biomedical Engineering
(ABME), entitled “Comparison of methemoglobin, deoxyhemoglobin, and ferrous nitrosyl
hemoglobin as potential MRI contrast agents” by Roya Ayati et al., 2022. I hereby confirm that
the use of this article is compliant with all publishing agreements.

4.1 Introduction
Magnetic resonance imaging (MRI) is a widely utilized medical diagnosis tool for
imaging the anatomy and physiological aspects of the body. Gadolinium-based contrast agents
(GBCA) are utilized to improve the MRI signal intensity which provides more distinct images. It
has been shown that the MRI signal intensity (T1-weighted images) in the brain is higher for
patients who had multiple exposures to GBCA compared to patients who had never had exposure
to GBCA [2, 3]. For those exposed to GBCA, gadolinium has been detected in all brain areas
with higher concentrations in the globus pallidus and dentate nucleus [4] although the long-term
effects of GBCA exposure in the brain are unknown. Furthermore, using GBCA has restrictions
for people with acute kidney injury and chronic kidney disease [5]. Additionally, the chance of
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nephrogenic systemic fibrosis occurrence for people on dialysis is higher after receiving GBCA
[7]. Due to these GBCA limitations, there is a need to identify alternative contrast agents that
minimize accumulation in the brain and can be more broadly used. Further, some individuals
may need an intravascular agent for specific indications.
A desirable contrast agent should be paramagnetic and contain unpaired electrons that
lastingly alter the T1 relaxation time in tissue while also being less toxic than GBCA.
Methemoglobin (metHb) is a paramagnetic blood constituent that can be potentially used as an
alternative contrast agent. MetHb is an oxidized form of hemoglobin in which the iron in the
heme group is in the 𝐹𝑒 !" (ferric) state where it is not capable of carrying oxygen. MetHb can be
produced by exposing oxyhemoglobin (oxyHb) to nitric oxide (NO) gas. The total hemoglobin
in human blood naturally contains 1-2% metHb due to endogenous reactions although metHb
can be tolerated at up to 20% in some individuals [11]. Sodium nitrite (NaNO2) has been used to
acutely increase metHb levels up to 5% to 12% with infrequent unpleasant side effects in healthy
adult human volunteers [39]. One of 10 subjects experienced nausea and hypotension while
receiving an intravenous dose of 300 mg over a period of one hour. One advantage of using
metHb is that it is gradually converted back to functioning hemoglobin through naturally
occurring reductive pathways involving cytochrome b5 or flavin [12]. Thus, metHb will not
deposit in the body under repeated scans. In addition to metHb, deoxyhemoglobin (HHb) has
paramagnetic properties which also makes it potentially useful in MRI investigations.
The potential utilization of metHb and/or HHb as contrast agents has previously been
investigated. In assessing metHb as a contrast agent, a mixed-breed canine with hereditary
methemoglobinemia (high levels of metHb) was used to create T1-weighted images [13]. After
treating the canine with methylene blue, which decreased the amount of metHb in blood, it was
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shown that the T1-weighted signal intensity of MRI decreased as the amount of metHb
decreased. In another study assessing HHb as a contrast agent [14], it was demonstrated that an
increasing amount of HHb during transient hypoxia enhanced the MRI signal. Thus, metHb
and/or HHb can potentially be used as contrast agents to replace GBCA. However, it is unknown
as to whether metHb or HHb would be a stronger and more appropriate contrast agent and to
what extent the T1-weighted signal is affected by concentration. This study evaluated T1weighted images of blood samples over a range of metHb and HHb concentrations to determine
which hemoglobin species lowers the T1 relaxation time, leading to more contrast and brightness
in MRI images.

4.2 Materials and Methods
Heparin sodium salt was purchased from Millipore Sigma (Burlington, MA). Fresh
bovine blood (1000 ml) was collected from a slaughterhouse and immediately treated with
heparin (10 U/ml) to prevent coagulation during blood collection. After collection, the blood was
refrigerated (4 °C) for up to two weeks until used. Certified 50% NO/50% nitrogen (N2) gas and
99.998% N2 gas were provided from Airgas (Radnor, PA). Sodium hydroxide pellets were
purchased from Sigma Aldrich (St. Louis, MO) to prepare a 0.5M sodium hydroxide solution.
Polydimethylsiloxane (PDMS) tubing (1.47mm ID and 1.96mm OD) was purchased from
Scientific commodities Inc. (Lake Havasu City, AZ).

4.3 MetHb and HHb Production and Analysis.
MetHb and HHb were produced using the system shown in Figure 2.1. In order to
remove possible NOx contaminants from the NO gas source, such as N2O3 and NO2, the NO gas
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source was continuously passed through a deoxygenated 0.5M NaOH solution. The gas then
flowed into a chamber containing gas-permeable PDMS tubing and then exited to a fume hood.
The gas flow rate was 20 ml/min. The chamber contained 5 PDMS tubes (each 4 feet long)
connected at each end to a single tube that allowed blood to continuously flow through the
PDMS tubing while the exterior of the tubing was exposed to either N2 or NO/N2 gas. Prior to
the experiment, the chamber was purged of oxygen by continuous passing N2 gas before
switching to the desired gas. MetHb was produced by exposing the PDMS tubing to NO/N2 gas.
HHb was produced by exposing the PDMS tubing to N2 gas. The single tubes were connected to
a blood reservoir (150 ml) that was at room temperature (24 °C) and continuously stirred at 130
rpm. The head space of the blood reservoir was exposed to room air for metHb production and to
N2 for HHb production. Blood was pumped from the reservoir and into the PDMS tubing at 20
mL/min using a peristaltic pump.
When oxyHb is exposed solely to N2, HHb is produced while oxyHb is depleted. When
oxyHb is exposed to NO, metHb is produced in addition to ferrous nitrosyl hemoglobin
(HbIINO) and ferric nitrosyl hemoglobin (HbIIINO). Here, the Hb subscripts of the latter two
species refer to the ferrous (II) and ferric (III) state of the iron in hemoglobin. The specific
reactions involving NO are:
$!

𝑜𝑥𝑦𝐻𝑏 + 𝑁𝑂 → 𝑚𝑒𝑡𝐻𝑏 + 𝑁𝑂!%
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r2= k2K2(metHb)(NO)

(4.2b)

r3= k3(HHb)(NO)

(4.3)

Reaction 4.1 is the reaction between oxyHb and NO to make metHb and nitrate (NO3-)
with k1= 5.4 x 106 mM-1min-1 (at pH=7, 20°C, cell-free hemoglobin) [21]. Following the
formation of metHb and in the presence of continual NO delivery, metHb reacts with NO to form
HbIIINO as shown in Reaction 4.2a. Reaction 4.2a is in rapid equilibrium (K2 = 10 mM-1) and
once HbIIINO is formed it is reduced to HHb via reaction 4.2b with k2 = 0.072 min-1 [37]. The
rate of reaction for metHb conversion to HHb is given as r2, which is a combination of reactions
4.2a and 4.2b. It is also known that S-nitroso-hemoglobin can be formed in competition with
reaction 4.2b [37], although the high NO delivery rate of this study would make this reaction
inconsequential. HHb can then undergo further reaction according to Reaction 4.3 (k3 =1.5 x 106
mM-1min-1 [24]) such that HbIINO is the observed nitrosated hemoglobin species, rather than
HbIIINO, of the reaction of metHb with NO [26]. Since the reaction of NO with hemoglobin
constituents in red blood cells is approximately 3000-fold slower compared to cell-free
hemoglobin [34], the reaction rates r1, r2, and r3 would be 3000 times smaller than the predicted
rates using the rate and equilibrium constants noted above. As long as oxyHb is present in the
blood reservoir, r1 is much faster than r2, such that metHb would be the main observable
hemoglobin constituent. Since HbIINO can be significantly formed following metHb formation
and is also paramagnetic, an analysis of HbIINO as a contrast agent in comparison to metHb or
HHb was also determined.
At various time points following exposure of blood to N2 or N2/NO gas, blood samples
were collected in 5 mL glass vials for MRI analysis. Since there was a low concentration of
NO2- or possibly dissolved NO in the collected samples, there was a potential for the hemoglobin
constituent concentrations to change prior to MRI analysis. Therefore, sample stability was
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assessed every 30 minutes for two hours by measuring hemoglobin constituent concentrations in
some of the samples.
MetHb, HHb, and oxygenated hemoglobin (oxyHb) were measured in blood samples
using the Radiometer ABL80 Flex gas analyzer (Radiometer, Brea, CA). However, the
radiometer was not capable of measuring hemoglobin species such as ferrous nitrosyl
hemoglobin (HbIINO) and ferric nitrosyl hemoglobin (HbIIINO). Therefore, a UV-1700
Shimadzu spectrophotometer was used to measure these species as well as metHb, HHb, and
oxyHb. For the spectrophotometric method, blood was diluted with water (2 drops of blood in
4mL of water) to reduce the absorbance of the sample to the desired level. Absorbance was
measured using wavelength ranges from 470 to 650 nm in 5 nm increments. Using the extinction
coefficients of HbIINO, HbIIINO, and metHb [37] , as well as those of oxyHb and HHb [38], an
excel solver was used to obtain all hemoglobin constituent concentrations by minimizing the sum
squared error between the measured absorbances at each wavelength and the calculated
absorbances using extinction coefficients. An agreement of the metHb amount measured by the
spectrophotometer with the amount measured by the radiometer analysis confirmed the accuracy
of the spectrophotometric method. Nitrite (NO2-), another byproduct during blood exposure to
NO, was measured at 540 nm using a microplate reader (BioTek Synergy Mx, Winooski, VT)
following the addition of Griess reagent [40].

4.3.1

MRI Analysis
The T1 relaxation times for each sample were acquired in the following manner. The

samples were allowed to equilibrate at room temperature for 10 minutes prior to MRI analysis.
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For MRI analysis, the vials containing the samples were then placed at the center of a 16-channel
head coil inside a 3 Tesla magnetic resonance imaging scanner (TRIO, Siemens, Erlangen, DE),
with the long axes of the vials parallel to the magnetic field. Transverse image slices of the vials,
oriented orthogonal to their long axis, were acquired using a 2-D, multi-slice, inversion-recovery,
turbo-spin-echo sequence. Scan parameters were TR: 2.1 s, TE: 9 ms, field of view: 200 x 100
mm, image matrix size: 384 x 192 pixels, echo train length: 24, bandwidth: 283 Hz pixel-1,
slices: 8, slice thickness: 5 mm, slice spacing: 1.5 mm, resolution: 0.52 x 0.52 x 5 mm, inversion
recovery times: 200, 300, 500, 700, 900, and 1500 ms, total scan time: 21 minutes. All images
were reconstructed using a vendor-provided, phase-preserving coil combination and
reconstruction method. The bulk T1 relaxation time for each sample was estimated by first
importing the reconstructed images into Matlab (Mathworks, Natick, MA) and using Otsu’s
method to segment each sample vial to obtain a signal intensity. An erosion operator was used to
discard pixels on all vial edges that could contain partial volume effects. To reduce the effects of
electrical noise, and for each inversion recovery time, all remaining pixels within a single
segmented vial were averaged together. The T1 relaxation time was numerically estimated using
the optimized global search method described by Barral et al. [41] by fitting the averaged signal
intensity values for each sample as a function of the inversion recovery time. The inversion
recovery time changes the observed brightness of a tissue, and it can be chosen arbitrarily and is
frequently modified and changed in a clinical setting to favorably alter the relative brightness of
different tissues.
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4.4 Results
Figure 4.1 shows a representative profile of hemoglobin constituents in the blood
reservoir during continuous NO delivery to the blood. The experiment was repeated 5 times. As
shown, oxyHb decreased until it completely disappeared within 50 minutes. As oxyHb
decreased, primarily metHb and some HbIINO increased until metHb reached a maximum level.
As expected, no HbIIINO or HHb was detected. After metHb reached the maximum, HbIINO
formation accelerated until metHb and HbIINO reach equilibrium. According to reactions 4.2a,
4.2b, and 4.3, it was expected that metHb should eventually be completely reduced to HbIINO.
However, since HbIINO and metHb reached equilibrium after 150 minutes, it is feasible that
reactions 4.2b and 4.3 could be reversible.
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Figure 4.1 Hemoglobin constituent concentrations in the blood reservoir following continuous exposure to NO.
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To have reliable data for Figure 3.2, the experiment was repeated 5 times. The average
time in which the amount of metHb reaches maximum is 52 ± 9.4 min considering 95%
confidence interval. Also, the average amount of metHb at the maximum time is 78.5 ± 7.9% and
the amount of HbIINO at 120 min is 67 ± 16% considering 95% confidence interval.
Samples of metHb and HbIINO at various time points in Figure 4.1 were used for the
MRI analysis. Since there was a short time delay (10 to 20 minutes) between collecting blood
samples and performing the MRI analysis, the stability of samples was measured to evaluate
potential changes between blood collection and MRI analysis. The metHb from blood samples
taken between 0 to 30 minutes of NO delivery was assessed for stability over a 120-minute
range. Figure 4.2A represents the stability of three different vials containing different initial
amounts of metHb. As shown, the %metHb is not stable and increases with time. One possible
reason for unstable metHb is the presence of nitrite (NO2-) in blood since NO2- is known to react
with oxyHb to make metHb [8]. Figure 4.1 shows that oxyHb was present in samples taken
between 0 to 30 minutes. As previously stated, an NaOH solution was used to minimize any
NOx contamination from the NO cylinder. These potential contaminants would produce NO2- in
blood. Though the NaOH solution greatly minimized NO2- formation, some NO2- was detected.
Therefore, to provide the most accurate measurement of metHb during MRI analysis when
oxyHb was present, samples of metHb were quickly analyzed by the MRI after samples were
provided (within a maximum of 15 minutes). Additionally, the %metHb from all samples was
measured again at the same time the MRI analysis was performed and this measured amount was
used when reporting the MRI results.
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Figure 4.2 The stability of a range of blood samples of metHb (A), HbIINO (B), and HHb (C)
following NO delivery to blood.

The HbIINO from blood samples taken between 50 to 90 minutes of NO delivery was
assessed for stability over a 120-minute range. Figure 4.2B represents the stability of three
different vials containing different initial amounts of HbIINO (the rest of hemoglobin in each vile
is in the form of metHb). As shown, the %HbIINO is stable. It is notable that the amount of
metHb in the presence of HbIINO was also stable since oxyHb was not present (data not shown).
Thus, no additional adjustments were needed when reporting the HbIINO amount (or metHb
amount in presence of HbIINO) for the MRI results.
Since there was also a desire to compare the MRI results of metHb and HbIINO with
those of HHb, HHb was formed by exposing oxyHb to N2 (rather than NO) in the delivery
system to remove oxygen from hemoglobin. HHb (95-100%) was made within 1.5 hours.
Figure 4.2C represents the stability of three different vials containing different initial amounts of
HHb. As shown, the %HHb remained stable for 120 minutes. Thus, no additional adjustments
were needed when reporting the HHb amounts for the MRI results.
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Once samples were analyzed with the MRI, the method previously described was used to
determine the T1 relaxation value as a function of %metHb, %HbIINO, and/or %HHb. Figure
4.3 shows representative examples for obtaining a T1 value for a 13.9%, 34.3%, and 58% metHb
samples. Here, the average signal intensity is plotted versus the inversion recovery times. The
lines, which show an excellent fit, represent the model of Barral et al. [41] used to find the T1
value. Here, the T1 values for 13.9%, 34.3%, and 58% metHb are 1159 ± 5 ms, 810 ± 3 ms,
and 649 ± 3 ms respectively (95% confidence intervals).

Figure 4.3 Signal intensity vs Inversion Recovery Times for 13.9%, 34.3%, and 58% metHb. Model of Barral
et al. [1] is shown as a solid line, resulting in T1 values 1159 ±5 ms, 810 ± 3 ms, and 649 ± 3 ms
respectively.

38

Figure 4.4 shows the images (at an inversion recovery time of 700 ms) obtained from the
MRI analysis of five samples of blood containing different amounts of metHb and HbIINO. The
associated T1 values are also shown. As shown, when the amount of metHb increases, the signal
intensity increases (images get brighter) and the T1 value decreases. A lower T1 value compared
to the 0% value is favorable for imaging. It is notable that at 7% to 21% metHb, the T1
decreases significantly (from 1116 to 948), which demonstrates the ability of metHb for being
used as a contrast agent at levels that can potentially be tolerated transiently by some individuals.

Figure 4.4 MRI Images at an inversion recovery time of 700 ms for varying amounts of
metHb and HbIINO along with associated T1 values.

To provide intuition regarding the ability of paramagnetic blood species to be used as a
contrast agent, the T1 values for metHb, HHb, and HbIINO were compared as a function of the
amount of these species. According to Gai et al. [42], the relationship between T1 and the
concentration (𝐶] ) of the contrast agent is:
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+
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+

= N+ + 𝑟] ∙ 𝐶]

(4.4)
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Here, T10 is the T1 value in the absence of all paramagnetic hemoglobin species (i.e. only
oxyHb is present). T1j is the T1 value of paramagnetic hemoglobin species j at a given
concentration 𝐶] in the absence of other paramagnetic hemoglobin species. Since 𝐶] is the
fractional amount of species j (𝑓] ) multiplied by the total concentration 𝐶N (approximately 1.82.1 mM for this study), a plot of 1/T1j vs. 𝑓] would give a slope of 𝑟] 𝐶N and an intercept of 1/T10.
A higher slope (representing lower T1 values compared to other species) would represent a
stronger contrast agent.
Using the experimental results, plots based on Equation 4.4 were made for metHb or
HHb with only oxyHb (non-paramagnetic) as the other species that was present. As metHb
reacts with NO to ultimately make HbIINO, HbIINO in the presence of only oxyHb was not
possible since some metHb would still be present. To utilize Equation 4.4 for HbIINO in the
absence of other paramagnetic species, the value of HbIINO at 𝑓K^77 GH =0.8 (with 𝑓<4*K^ =0.2)
was utilized as a reference point. With T10 obtained from the metHb and HHb studies, the slope
for HbIINO was estimated by using the average T10 value from metHb and HHb.
Figure 4.5 shows the liner fit of Equation 4 for metHb, HHb, and HbIINO. The 95%
confidence intercept of the lines for metHb (0.00075 ± 0.00010 ms-1) and HHb (0.00065 ±
0.00005 ms-1) are nearly the same, with an average intercept 1/T10 value of 0.00070 ms-1. Thus,
T10 representing oxyHb is ~1500 ms. For comparison, the T1 value for 92% ± 7% oxyHb in
human blood is reported as 1664 ± 14 ms [43], which is consistent with this work. The 95%
confidence slope of the linear line (𝑟] 𝐶N ) for metHb is 1.63 ± 0.19 × 10%! ms-1, for HHb is
0.26 ± 0.08 × 10%! ms-1, and for HbIINO is 0.66 ± 0.55 × 10%! ms-1. Comparing the slopes
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of each paramagnetic species, metHb has a significantly higher slope than the other two species,
demonstrating that metHb would be the strongest contrast agent of the three. Also, the slope of
HbIINO is greater than HHb, which implies that HbIINO would be a better contrast agent
compared to HHb. With the slope for HHb not increasing very much, HHb is a relatively weak
contrast agent.

Figure 4.5 T1 vs fraction of blood species (fj) for metHb, HHb, and HbIINO. The HbIINO predicted value is based
on Equation 5.

Finally, it is possible that the HbIINO slope in Figure 4.5 could be different since it was
assumed that no other paramagnetic species besides HbIINO were present at 𝑓K^77 GH near 0.8.
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Since the data in Figure 4.5 for HbIINO were from a mixture of only HbIINO and metHb,
𝑇1K^77 GH,' near 𝑓K^77 GH = 0.8 in the absence of metHb was estimated according to:
𝑇1<1_ =

'-8/9: ∙N+-8/9:,< "'9:77 *+ ∙N+9:77 *+,<
'-8/9: "'9:77 *+

(4.5)

Here, 𝑇1<1_ is the measured value of the mixture (represented by open squares in Figure
4.5), 𝑇1<4*K^,' represents the T1 value for metHb (without any other paramagnetic species) at
the given value of 𝑓<4*K^ , and 𝑇1K^77 GH,' represents the T1 value for HbIINO (without any other
paramagnetic species) at the given value of 𝑓K^77 GH . Since T1mix, 𝑓K^77 GH , 𝑓<4*K^ , and
𝑇1<4*K^,' are known, 𝑇1K^77 GH,' could be predicted. As shown in Figure 4.5, the predicted
𝑇1K^77 GH,' values are very similar to the mixed T1 values when 𝑓K^77 GH is near 0.8. This
suggests that the slope for HbIINO is likely an appropriate representation for comparison with the
slopes for metHb and HHb.

4.5 Discussion
To replace GBCA with a safe MRI contrast agent, metHb and HHb have previously been
considered. In this work, metHb was made using an NO gas delivery system. Paramagnetic
properties that are essential for contrast agents are due to the presence of unpaired electrons. For
HHb, four unpaired electrons remain as the oxygen releases from hemoglobin, making HHb a
paramagnetic substance [44]. On the other hand, metHb has 5 unpaired electrons on every iron
atom [45], which make metHb another paramagnetic blood species. As metHb has more
unpaired electrons than HHb, it is more likely that metHb is a stronger contrast agent compared
to HHb. This study confirmed that metHb is a much stronger contrast agent compared to HHb.
Figure 4.5 showed that the %HHb did not have a strong effect on changing the baseline T1
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value. Thus, HHb may only be an effective contrast agent for extremely transient imaging
because the amount of HHb needed to provide a significant contrast effect cannot be tolerated by
animals or humans for a sustained period of imaging.
HbIINO, another paramagnetic species, was also produced as metHb reacted with NO.
This study showed for the first time that HbIINO can provide a contrast effect. This effect is
more significant than HHb but much less than metHb. Since a metHb/oxyHb combination
provides better contrast than a metHb/HbIINO/oxyHb combination, it is desirable that metHb be
produced as a contrast agent while minimizing the production of HbIINO. When using NO to
produce metHb, this can be accomplished by minimizing the exposure of metHb to NO once
metHb is nearly produced.
As stated earlier, metHb can be tolerated at up to 20% in some individuals [11].
However, since metHb decreases the oxygen carrying capacity of blood and might not be safe for
individuals who cannot tolerate a transient decrease in oxyhemoglobin, a more detailed
investigation is needed to assess the lower limit of metHb that can be effective for serving as a
contrast agent. This knowledge would provide insights towards limiting the clinical risks of
methemoglobin modulation. Finally, future work can also include evaluating additional methods
for the production and delivery of metHb for use as an effective contrast agent.
MetHb has shown the ability to decrease the T1 significantly, according to Equation 4.4,
with a slope of 𝑟] 𝐶N = 1.63 ± 0.19 s-1. With 𝐶N approximately 2 mM, rj for metHb would be 0.82
mM-1s-1. In comparison, studies have shown that rj for GBCAs is 3.3 ± 0.2 mM-1s-1 for GdDTPA at 3Tesla in human blood plasma [46]. Thus, GBCAs at equivalent concentrations would
have a much better ability to decrease the T1 than metHb and provide greater contrast. However,
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as shown in this work, metHb can still be considered a good candidate as a contrast agent,
especially for people who cannot use GBCAs.
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5 Conclusion and Future Work
Due to the safety concerns for gadolinium-based contrast agents (GBCAs), the demand
for having a safe contrast agent has been increased in order to overcome the issues with
GBCAs. Methemoglobin (metHb) and oxygen-free hemoglobin (HHb) are two forms of
hemoglobin that have the capacity to be used to enhance the contrast in the MRI images since it
has been shown that the T1-weighted signal intensity of blood is changed during MRI scans for
metHb and HHb, leading to enhanced contrast of MRI images. The ability of metHb and HHb
to change the signal intensity has led to the hypothesis that they can be used as effective
contrast agents. MetHb can be made by exposing oxyhemoglobin (oxyHb) to nitric oxide (NO)
and HHb can be made by removing the oxygen from hemoglobin using nitrogen (N2).
The reaction between metHb and NO ultimately results in the formation of another form
of hemoglobin called ferrous nitrosyl hemoglobin (Hb[[ NO) (reaction 3.1) and the amount of
Hb[[ NO can be measured using a spectrophotometric method. Additionally, as NO is delivered
to oxyHb, the metHb amount increases until all of the oxyHb is consumed. As metHb is fully
produced, it starts to react with NO to make Hb[[ NO.
In this study, an NO delivery system was successfully designed and implemented to
deliver NO to blood to produce metHb, and plug flow reactor modeling of metHb formation
using the NO delivery system was in agreement with the experimental results. Additionally,
nitrite (NO2-) formation was experimentally detected. As there were likely impurities in the gas
source that caused NO2- formation in blood, the amount of NO2- formed during metHb
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formation was reduced by bubbling the NO gas sources through a 0.5 M NaOH solution. As
the NO2- that was formed could not be completely eliminated, even when the concentration of
NaOH was increased, future work can be done on eliminating NO2- formation in the blood
during the delivery of NO.
It was unknown that whether metHb or HHb would be a stronger and more appropriate
contrast agent and to what extent the T1-weighted signal was affected by concentration. This
study evaluated T1-weighted images of blood samples over a range of metHb and HHb
concentrations, as well as HbIINO concentrations. Comparison of T1 values showed that metHb
is the strongest contrast agent and that HHb is a relatively weak contrast agent. This study
showed for the first time that HbIINO can provide a contrast effect, although not as strong as
metHb but stronger than HHb. With metHb providing a viable contrast between 10-20%,
metHb has the potential to be a safe and effective contrast agent since it can be naturally
converted back to hemoglobin.

5.1 Future Work
As it mentioned before, future work can be done on eliminating NO2- in the blood while
exposing oxyHb to NO by finding the source of NO2- formation. The source of NO2- can be due
to more contamination in the NO source gas, which cannot be removed by bubbling NO in the
NaOH solution. Also, the source of NO2- can be due the reaction of NO with one of the blood
components such as proteins or chlorine content of the blood. Nevertheless, the source of NO2should be investigated in the future work to reduce the amount of NO2- during metHb
formation.
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Additionally, developing new methods to make transient metHb concentration (besides
oxyHb exposure to NO) in human body can be considered as a possible future work. Finding a
safe method to make or deliver metHb to human body can be done by either circulating
patience’s blood in a chamber while exposing it to the NO, or delivering metHb to the human
blood to increase the concentration of metHb. Finding a method that helps make metHb in
human blood with less difficulties can increase the chance of using metHb as a common
contrast agent.
Also performing MRI studies while metHb is circulating throughout the body would be
important for investigating the effectiveness of using metHb as a contrast agent. However, MRI
studies should be done on animals first by increasing the metHb concentration and performing
additional MRI studies to make sure that metHb can produce desirable results such as more
detailed images.
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